目的 探讨康莱特注射液联合埃克替尼治疗非小细胞肺癌的临床疗效。方法 选取2013年4月-2015年8月保定市第三中心医院收治的非小细胞肺癌患者86例，随机分为对照组和治疗组，每组各43例。对照组口服盐酸埃克替尼片，125 mg/次，3次/d。治疗组在对照组基础上静脉输注康莱特注射液，200 mL/次，1次/d。两组患者均治疗3个疗程，1个疗程21 d，疗程间隔3～5 d。观察两组的临床疗效，比较两组生存质量和免疫功能的情况。结果 治疗后，对照组和治疗组有效率分别为34.88%、60.47%，临床获益率分别为69.77%、88.37%，两组比较差异有统计学意义（P<0.05）。治疗后，对照组和治疗组的改善率分别为34.88%、58.14%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组CD3⁺、CD4⁺、CD4⁺/CD8⁺和NK明显高于治疗前，治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的明显高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 康莱特注射液联合埃克替尼治疗非小细胞肺癌具有较好的临床疗效，可改善患者的生活质量，提高机体免疫功能，具有一定的临床推广应用价值。

Objective To evaluate the clinical effect of Kanglaite Injection combined with icotinib in treatment of non-small cell lung cancer. Methods Patients (86 cases) with non-small cell lung cancer in the Third Central Hospital of Baoding from April 2013 to August 2015 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were po administered with Icotinib Hydrochloride Tablets, 125 mg/time, three times daily. Patients in the treatment group were iv administered with Kanglaite Injection on the basis of the control group, 200 mL/time, once daily. Patients in two groups were treated for 3 courses, 1 course of 21 d, treatment interval of 3-5 d. After treatment, the clinical efficacies were evaluated, and quality of life and immune function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 34.88% and 60.47%, respectively, the clinical benefit rates in the control and treatment groups were 69.77% and 88.37%, respectively, and there was difference between two groups (P<0.05). After treatment, the improvement rates in the control and treatment groups were 34.88% and 58.14%, respectively, and there was difference between two groups (P<0.05). After treatment, CD3⁺, CD4⁺, CD4⁺/CD8⁺, and NK in the treatment group were higher than those before treatment, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Kanglaite Injection combined with icotinib has clinical curative effect in treatment of non-small cell lung cancer, can improve quality of life, and increase immune function, which has a certain clinical application value.